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OBJECTIVES We investigated whether the addition of 24 h of continuous vectorcardiography ST segment
monitoring (cVST) for an early (within 24 h of the latest episode of angina) determination
of cardiac troponin T (cTnT) could provide additional prognostic information in patients
with unstable coronary artery disease (UCAD), i.e., unstable angina and non–Q wave
myocardial infarction.
BACKGROUND Determination of cTnT at admission and cVST are individually reported to be valuable
techniques for the risk assessment of patients with UCAD.
METHODS Two hundred and thirty-two patients suspected of UCAD were studied. Patients were
followed for 30 days, and the occurrence of cardiac death or acute myocardial infarction
(AMI) were registered.
RESULTS One ST segment episode or more (relative risk [RR] 7.43, p 5 0.012), a cTnT level $0.20
mg/liter (RR 3.85, p 5 0.036) or prestudy medication with calcium antagonists (RR 3.31, p 5
0.041) were found to carry independent prognostic information after multivariate analysis of
potential risk variables. By combining a cTnT determination and subsequent cVST for 24 h,
subgroups of patients at high (25.8%) (n 5 31), intermediate (3.1%) (n 5 65) and low risk
(1.7%) (n 5 117) of death or AMI could be identified.
CONCLUSIONS Twenty-four hours of cVST provides additional prognostic information to that of an early
cTnT determination in patients suspected of having UCAD. The combination of biochemical
and electrocardiographic methods provides powerful and accurate risk stratification in UCAD. (J
Am Coll Cardiol 1999;33:1519–27) © 1999 by the American College of Cardiology
Patients with unstable angina pectoris (UAP) and non–Q
wave myocardial infarction (nQMI) are often grouped
together due to similarities in pathophysiology and clinical
presentation (1,2). In the present study, UAP and nQMI
are referred to as unstable coronary artery disease (UCAD).
Within days or weeks after the clinical presentation, patients
with UCAD are at high risk of subsequent cardiac death,
myocardial infarction, reinfarction and disabling angina
(3,4). However, these patients are heterogeneous regarding
the severity of the disease, the clinical presentation and the
prognosis (1–5). Therefore, early risk assessment is essential
in cases of UCAD to allocate treatment resources appropri-
ately.
An elevated plasma level of the cardiac structural protein
troponin T (cTnT) at admission has been associated with a
poor clinical outcome in UCAD (6–11). Episodes of
transient myocardial ischemia detected by ambulatory elec-
trocardiogram (ECG) recording (12–14) or continuous
vectorcardiography ST segment monitoring (cVST) (15–
18) have been associated with adverse clinical outcome in
such patients as well. In contrast to ambulatory ECG
recording, cVST has the potential for real-time analysis
without the need for time-consuming retrospectively per-
formed analysis. Because cTnT reflects previous myocardial
damage, and ongoing active coronary artery disease is
evidenced by cVST, these methods are chronologically
complementary. Therefore, the aim of the present study was
to determine whether cVST for 24 h could provide addi-
tional prognostic information for an early cTnT determina-
tion in patients with UCAD.
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METHODS
Study patients. The present investigation was carried out
as a substudy of the Thrombin Inhibition in Myocardial
Ischemia (TRIM) trial, a prospective double-blind random-
ized multicenter trial conducted in Scandinavia from De-
cember 1994 through July 1995. The purpose of the main
study was to investigate the efficacy of a new specific
thrombin inhibitor (inogatran) in patients with UCAD
(19). Patients between 25 and 80 years of age suspected of
having UCAD were eligible. Patients were required to have
new onset of ischemic chest pain or rapid deterioration of
previously stable effort angina or onset of angina at rest.
Time for inclusion was within 24 h of the latest episode of
angina (qualifying episode of angina). At least one of the
following criteria had to be present in order to comply with
the diagnosis of UCAD: ECG changes compatible with
myocardial ischemia, i.e., ST depression or T wave inversion
($0.1 mV in at least two contiguous leads), or a history of
previous myocardial infarction, positive coronary angiogra-
phy, positive myocardial scintigraphy or a positive exercise
test. The main exclusion criteria were any condition con-
sidered to increase the risk of bleeding. Patients who had
been treated with oral anticoagulants, heparin or fibrinolytic
drugs within one week before screening were excluded from
participation, as were patients with impeding acute myocar-
dial infarction (AMI) and indication for thrombolytic ther-
apy. Patients with percutaneous transluminal coronary an-
gioplasty (PTCA) or coronary artery bypass graft surgery
(CABG) performed within three months were also ex-
cluded. Moreover, patients with uncontrolled heart failure,
uncontrolled cardiac arrhythmia, serum creatinine
.150 mM, hemoglobin ,100 g/liter (6.21 mM), drug or
alcohol abuse or known liver disease were excluded.
A total of 1,209 patients from 60 centers were included in
the TRIM study. Of these, 232 patients from 10 centers had
blood samples drawn and cVST performed for the present
substudy. Written informed consent was obtained from all
patients. The protocol was approved by the regional Scien-
tific Ethical Committees of the participating centers.
Evaluation of index events. An index event was retrospec-
tively diagnosed as either UAP or nQMI based on the
clinical course, ECG changes and maximum plasma levels
of cardiac markers available at each participating center
(either total creatine kinase [CK], CK isoenzyme MB
catalytic activity or CK-MB mass) obtained within 6 h of
inclusion.
Evaluation of end-points. The end point was a composite
of the events cardiac death and AMI. Patients were fol-
lowed for 30 days. Acute myocardial infarction was consid-
ered present when two of the following criteria were
complied with: 1) typical anginal chest pain of at least
20 min duration; 2) a diagnostic ECG (new Q-wave
$0.04 s and $1 mm or Q/R .1/3, or ST elevation $2 mm
in precordial or $1 mm in other leads followed by T wave
inversion in at least two leads in two consecutive record-
ings); or 3) an increase in cardiac enzymes above the upper
reference occurring separately from any elevation taking
place at inclusion (reinfarction). Cardiac events were eval-
uated by an independent End point Committee.
Treatment. Patients were randomized to one of three dose
levels of inogatran or heparin (19). Treatment was given as
an intravenous infusion for 72 h. All patients received
low-dose aspirin daily if tolerated. Nitrates, beta-blockers
and calcium channel blockers were administered at the
discretion of the treating physician. Patients’ medications
before inclusion are listed in Table 1. The need for coronary
angiography, coronary angioplasty or CABG was deter-
mined by the treating physician.
Methods. An ECG was obtained at inclusion. The ECGs
were interpreted by the local investigators and categorized
according to the predominant ST/T segment status (ST
elevation, ST depression, T wave inversion or any ST/T
change). Blood specimens were obtained according to a
predefined time schedule in the main TRIM trial (19). For
the purpose of this study, a cTnT level was determined from
a blood specimen obtained at inclusion. Venous whole
blood was drawn into heparin-containing tubes that were
centrifuged at 2,000 g for a period of 20 min. The plasma
was kept at 280°C and sent for analysis at the core
laboratory of Aarhus University Hospital (Aarhus, Den-
mark). All measurements were performed by laboratory
personnel without knowledge of the patients. Cardiac tro-
ponin T was measured using an enzyme-linked immunosor-
bent assay [ELISA Troponin(e) T] on the ES 300 analyzer
(Boehringer Mannheim GmbH, Mannheim, Germany).
The method is based on a single-step sandwich principle
with streptavidin-coated tubes as the solid phase and two
monoclonal antihuman cTnT antibodies. Detection limit of
the assay is 0.012 mg/liter. The method is described in detail
elsewhere (20).
Continuous vectorcardiography ST segment monitoring
was performed for 24 h after inclusion in all patients, using
the MIDA 1000 or Coronet systems (Ortivus Medical AB,
Ta¨by, Sweden). The method of ischemia monitoring using
vectorcardiography has previously been described in detail
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass grafting
cTnT 5 cardiac troponin T
cVST 5 continuous vectorcardiography ST segment
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ECG 5 electrocardiogram
nQMI 5 non–Q wave myocardial infarction
ST-VM 5 ST vector magnitude
UAP 5 unstable angina pectoris
UCAD 5 unstable coronary artery disease
1520 Nøgaard et al. JACC Vol. 33, No. 6, 1999
Cardiac Troponin T and Continuous ST Segment Monitoring May 1999:1519–27
(21). Briefly, the system consists of a data acquisition
module and an IBM-compatible personal computer. Elec-
trocardiographic signals are continuously collected from
eight conventional body surface electrodes positioned ac-
cording to Frank (22). Electrocardiographic complexes are
sampled for 1-min periods and averaged to form mean
vectorcardiographic complexes in three orthogonal leads: X,
Y and Z. The ST segment parameter studied was ST vector
magnitude (ST-VM), which is the summarized deviation of
the ST segment from the isoelectric level 20 ms after the J
point. At the end of each averaging period, ST-VM is
calculated and presented as a trend curve updated continu-
ously during the whole recording period. An illustrative
trend curve is shown in Figure 1. Recordings from patients
with bundle branch block, pacemaker in situ or with less
than 16 h recording time were not analyzed because cVST
had not been validated in such patients. Only the first 24 h
were analyzed from each recording. Recordings were stored
on floppy disks and sent for central analysis at Sahlgrenska
University Hospital (Gothenburg, Sweden). Analysis was
performed by personnel without knowledge of the patients.
Discriminator values for the differentiation between
high- and low-risk patients. In earlier studies, a cTnT
level of 0.20 mg/liter (8,23) was used as the discrimination
limit. However, a lowering of the cTnT cut-off value has
occurred in parallel with an advance in the immunoassay
technology, and today several studies have confirmed the
applicability of 0.10 mg/liter as the discriminator value in
the prognostic evaluation of patients with UCAD (7,24).
Therefore, in the present study, cTnT discriminator values
of 0.10 and 0.20 mg/liter, respectively, were studied. There
is no gold standard for the diagnosis of myocardial ischemia
by ST segment monitoring. However, based on previous
investigations, assessment of ischemic changes was per-
formed as one or more transient increases of ST-VM $50
mV from the individual baseline for .1 min (15,17,18).
Statistical analysis. In the statistical calculations of the
composite end-point, each patient was represented by one
cardiac event only. Due to nonnormal distribution, cTnT
and cVST data were presented as medians (interquartile
range [IQR], range). Group comparisons of continuous
variables were made by the Mann-Whitney U test, and
categorical variables were compared using the Chi-square or
Fischer exact test as appropriate. The Spearman rank-
correlation coefficient relating the number of ST-VM epi-
sodes to the level of cTnT was calculated. The variables in
Table 3 and Table 6 were evaluated by the Kaplan-Meier
method and the log-rank test to detect univariate predictors
of the composite end-point. Forward “stepwise” Cox regres-
sion analysis was performed in order to detect independent
predictors of the composite end point using all variables of
potential significance (p , 0.10) identified in the univariate
analysis. At first, baseline variables of potential significance
were evaluated in this multivariate model. Once these
independent baseline predictors were accounted for, the
added value of the cTnT level and ST segment monitoring,
respectively, were explored in a second multivariate analysis.
Two separate models were built to evaluate the independent
prognostic significance of each cTnT cut-off value. Accord-
ingly, three separate multivariate models were built. In the
multivariate models, a p value ,0.20 was used as the
criterion for selection. A p value ,0.05 was considered
statistically significant.
RESULTS
Characteristics of patients. A total of 232 patients were
included in the study. The index events were classified as
UAP in 152 (66%), nQMI in 74 (32%) and other diagnoses
in 6 (3%) patients. All patients with other diagnoses had a
Table 1. Baseline Characteristics of the Study Population
Total
(n 5 232)
cTnT
>0.20
mg/liter
(n 5 65)
ST-VM
>1
(n 5 69)
Male 162 (70) 46 (71) 44 (64)
Median age (range), years 63 (31–80) 64 (40–78) 66 (40–80)
Smokers: past and
(current)
141 (61) 41 (63) 40 (58)
Diabetes mellitus 40 (17) 12 (18) 11 (16)
Arterial hypertension 76 (33) 19 (30) 23 (33)
Previous AP (.4 weeks) 151 (65) 28 (43)* 44 (64)*
Previous AMI 102 (44) 25 (38) 30 (43)
Previous PTCA/CABG 43 (19) 5 (8) 8 (12)
Congestive heart failure 26 (11) 7 (11) 12 (17)
Medication at inclusion
Aspirin 118 (51) 23 (35)* 37 (54)*
Nitrates 141 (61) 23 (35)* 42 (61)*
Beta blockers 104 (45) 23 (35) 31 (45)
Calcium antagonists 68 (29) 13 (20) 18 (26)
Diuretics 49 (21) 14 (22) 18 (26)
ACE inhibitors 32 (14) 5 (8) 10 (14)
Digoxin 8 (3) 3 (5) 4 (6)
Duration from qualifying
episode of angina
to inclusion, hours
0 to 5 42 (23) 8 (12) 10 (14)
6 to 11 74 (27) 15 (23) 24 (35)
12 to 18 53 (22) 18 (28) 18 (26)
$19 63 (28) 24 (37) 17 (25)
Study-drug
Inogatran 177 (76) 49 (75) 57 (83)
Heparin 55 (24) 16 (25) 12 (17)
Final inclusion diagnosis
Non–Q wave AMI 74 (32) 52 (80)* 36 (52)*†
Unstable angina pectoris 152 (66) 9 (14)* 31 (45)*†
Other 6 (3) 4 (6) 2 (2)
If not stated otherwise, the values shown are number of patients and percentages of
the group. *p ,0.05 when the group was compared with the group on its left. †p
,0.05 when the group was compared with the second group on its left. If not
otherwise stated, comparison between groups revealed a p value $0.05.
ACE 5 angiotensin converting enzyme; CABG 5 coronary artery by-pass
grafting; PTCA 5 percutaneous transluminal coronary angioplasty.
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Q wave myocardial infarction. In contrast to UAP, nQMI
was a more frequent index event among patients with a
cTnT level $0.20 mg/liter or one ST-VM episode or more,
as compared with the total substudy population (Table 1).
Moreover, among patients with a cTnT level $0.20 mg/
liter, fewer had previous angina, or used aspirin or nitrates,
at inclusion as compared with patients with one ST-VM
episode or more and the total substudy group, respec-
tively. Otherwise, the two groups of patients had similar
baseline characteristics and were also representative of
the total substudy population. The median (IQR) time
from the qualifying episode of angina to inclusion was
12 h (7 to 18).
Cardiac troponin T and continuous ST segment moni-
toring. Two hundred and thirty-one, 223 and 214 patients,
respectively, had determination of the cTnT level, ECG
analysis and cVST analysis performed. The blood sample
was lost in one (0.4%) patient. Nine (3.9%) patients were
excluded from the ECG data analysis due to the presence of
bundle branch block. Eighteen (7.8%) patients were ex-
cluded from the ST segment monitoring analysis due to the
presence of bundle branch block (n 5 9), ,16 h of cVST
performed (n 5 4) and technical problems (loss of backup or
electrical interference) (n 5 5). Complete clinical, electro-
cardiographic, biochemical marker and ST segment moni-
toring data were obtained in 213 (92%) patients. Eighty-
seven (38%) patients had a cTnT value $0.10 mg/liter, 65
(28%) had a cTnT value $0.20 mg/liter and 69 (32%)
patients had one ST-VM episode or more. The median
level (IQR; range) of cTnT was 0.02 (0.00–0.23; 0.00–
3.69) mg/liter. The median number (IQR; range) of
ST-VM episodes was 0 (0–2; 0–24). The median time
(IQR; range) of cVST was 24.00 (23.59–24.00; 16.14–
24.00) h. Patients treated with inogatran had more ST-VM
episodes as compared with patients treated with heparin.
Treatment effect of the study drugs on cVST has previously
been described in detail (18). Among patients with one
ST-VM episode or more, the median level (IQR; range) of
cTnT was 0.15 (0.02–0.68; 0.00–3.69) mg/liter as com-
pared with 0.01 (0.00–0.13; 0.00–2.91) mg/liter in patients
Figure 1. Top, Trend curve of ST vector magnitude (ST-VM) from a patient with unstable angina as displayed by the vectorcardiography
monitoring system. Transient increases of ST-VM $50 mV from the baseline .1 min indicate episodes of myocardial ischemia. Bottom,
12-lead ECG tracings recorded at baseline (1) and during an episode of transient myocardial ischemia (2) as indicated on the trend curve.
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without ST-VM episodes (p 5 0.0003). The numeric
relationship between the number of ST-VM episodes and
the cTnT level at inclusion is presented in Table 2. There
was a moderate positive relationship between the number of
ST-VM episodes and the cTnT level (Spearman correla-
tion, rho 5 0.45, p , 0.0001).
Follow-up. Three (1.3%) patients died and 12 (5.2%)
patients had a nonfatal AMI during the 30 days of follow-
up. A coronary angioplasty or CABG was performed in 57
(25%) patients. A revascularization procedure was per-
formed in nine (of the 12) patients with an AMI. One
patient had an AMI 15 h after a CABG, otherwise, all
AMIs occurred before coronary angioplasty (median time
[range] from event to procedure: 7 [2 to 82] h) or CABG
(median time [range] from event to procedure: 84 [3 to 217]
h). Revascularization procedures were not performed in any
of the patients who died. Among 18 patients excluded from
the cVST analysis, two died (exclusion due to left bundle
branch block and ,16 h of monitoring time, respectively)
and one had an AMI (exclusion due to ,16 h of monitoring
time).
Predictors of cardiac death or acute myocardial infarc-
tion. The univariate predictive values of several risk vari-
ables are presented in Table 3. Of these, prestudy medica-
tion with calcium antagonists, an index diagnosis of nQMI,
inclusion ECG ST segment depression, a cTnT level $0.10
or $0.20 mg/liter at inclusion or one ST-VM episode or
more at 24 h of cVST were significantly associated with the
composite end-point. In one patient with a CABG-related
end-point (AMI), neither cTnT testing nor cVST were of
predictive value. In Figure 2, the cumulative percentage of
patients with event (death or AMI)-free survival is illus-
trated by Kaplan-Meier curves according to the level of
cTnT (cutoff value: 0.20 mg/liter) and the number of
ST-VM episodes (cutoff value: 1). There was no difference
in median time (range) from inclusion to the composite
end-point among those patients predicted by cTnT testing
as compared with those predicted by cVST: 80 (11 to 357)
versus 79 (23 to 199) h (p 5 0.84). By multivariate analysis
of baseline variables of potential significance, inclusion
ECG ST segment depression (risk ratio [RR] 3.09, 95%
confidence interval [CI] 0.97–9.77; p 5 0.055) and prestudy
medication with diuretics (RR 2.69, CI 0.84–8.53; p 5
0.093) or calcium antagonists (RR 2.35, CI 0.75–7.33; p 5
0.14) were retained in the final model. Table 4 shows the
risk ratios, confidence intervals and p values of risk variables
retained in a second multivariate model exploring the
relative value of the inclusion cTnT level (cut off value 0.20
mg/liter) and subsequent 24 h of cVST once the baseline
variables have been accounted for. One ST-VM episode or
more, a cTnT level $0.20 mg/liter and prestudy medication
Table 2. The Relationship Between the Number of ST Segment
Episodes and the Level of Cardiac Troponin T at Inclusion
Among Patients in Whom Both ST Segment Monitoring and
Biochemical Analyses Were Performed (n 5 213)
Number of ST-VM
Episodes
cTnT level (mg/liter)
Median IQR (Range)
0 (n 5 144) 0.01 0.00–0.13 (0.00–2.91)
1 (n 5 20) 0.14 0.01–0.53 (0.00–1.40)
2–3 (n 5 17) 0.14 0.28–1.13 (0.00–3.10)
4–8 (n 5 20) 0.17 0.04–0.64 (0.00–1.92)
$9 (n 5 12) 0.25 0.00–2.12 (0.00–3.69)
Spearman correlation, rho 5 0.45; p ,0.0001. IQR 5 interquartile range; ST-VM 5
ST vector magnitude.
Table 3. Univariate Analysis of Selected Risk Variables for
Cardiac Death/AMI at 30 Days
Relative
Frequency of
Patients with
Death/AMI, %
p Value
(Log-Rank)
Male/Female 5.6/8.6 0.39
Age $65 years yes/no 8.2/5.2 0.40
Medical history
Angina pectoris yes/no 6.0/7.4 0.68
Myocardial infarction yes/no 8.8/4.6 0.19
Congestive heart
failure
yes/no 15.4/5.3 0.05
Hypertension yes/no 7.9/5.8 0.56
Diabetes mellitus yes/no 5.0/6.8 0.67
Smoker yes/no 5.7/7.7 0.57
Preinclusion medication
Beta-blockers yes/no 8.7/4.7 0.22
Calcium antagonists yes/no 11.8/4.3 0.04
Diuretics yes/no 12.2/4.9 0.07
Nitrates yes/no 6.4/6.6 0.93
ACE inhibitors yes/no 9.4/6.0 0.46
Digitalis yes/no 0.0/6.7 0.45
Aspirin yes/no 7.6/5.3 0.46
At inclusion
$12 hours from
q.e.a.
yes/no 6.0/6.9 0.78
Chest pain yes/no 2.6/7.3 0.29
Final diagnosis
(nQMI)
yes/no 12.2/3.8 0.02
12-lead
electrocardiogram:*
ST elevation yes/no 10.0/6.1 0.63
ST depression yes/no 11.4/3.5 0.02
T wave inversion yes/no 6.1/6.5 0.91
Any ST/T change yes/no 7.4/3.3 0.27
Cardiac troponin T:†
$0.10 mg/l yes/no 11.5/3.5 0.02
$0.20 mg/l yes/no 15.4/3.0 0.0006
Study drug
Inogatran/heparin 7.3/3.6 0.32
ST-segment
monitoring‡
ST-VM $1 episodes yes/no 14.5/1.4 0.0001
*n 5 223, †n 5 231, ‡n 5 214 (see text). n 5 232 if not otherwise specified.
ACE 5 angiotensin converting enzyme; q.e.a. 5 time from qualifying episode of
angina to inclusion; ST-VM 5 ST vector magnitude.
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with calcium antagonists independently predicted death or
AMI at 30 days. By evaluating the cTnT cutoff of 0.10
mg/liter in a similar manner, only one ST-VM episode or
more (RR 8.48, CI 1.75–40.86; p 5 0.008) carried inde-
pendent prognostic information; also included in this final
model were prestudy medication with calcium antagonists
(RR 3.12, CI 0.98–9.85; p 5 0.053) and a cTnT level
$0.10 mg/liter (RR 2.32, CI 0.65–8.21; p 5 0.19).
Figure 3 shows the flow of all patients according to the
cTnT level at inclusion, the presence or absence of ST-VM
episodes within 24 h of inclusion and the occurrence of
death or AMI during 30 days of follow-up. The patients
with both a cTnT level $0.20 mg/liter and one subsequent
ST-VM episode or more had a 25.8% risk of death or AMI.
Among patients with a cTnT level $0.20 mg/liter and 0, 1
to 3, 4 to 8, or $9 ST-VM episodes, the event rate was 0%
(0/27), 11% (2/18), 44% (4/9) and 50% (2/4), respectively.
The event rate in patients with either of the methods
positive was 3.1% (2/65). In patients with both a cTnT level
,0.20 mg/liter and without ST-VM episodes, the risk of an
event was 1.7%. This low-risk group comprised 50.4% of
the total study population. The event rate for patients
ineligible of cVST analysis was 16.7% (3/18). Among this
subgroup of patients, those with a cTnT level $0.20
mg/liter had an event rate of 28.6% (2/7) as compared with
9.1% (1/11) in patients without an elevated cTnT level.
Unstable angina pectoris. Among patients in whom an
index event was categorized as UAP (n 5 152), those with
one ST-VM episode or more had a median cTnT level
(IQR; range) of 0.02 (0.00–0.07; 0.00–2.00) mg/liter as
compared with 0.00 (0.00–0.02; 0.00–1.09) mg/liter in
patients without ST-VM episodes (p 5 0.02). The numeric
relationship between the number of ST-VM episodes and
the cTnT level at inclusion among patients with UAP is
shown in Table 5. The positive relationship between the
number of ST-VM episodes and the cTnT level was
retained in this subset of patients (Spearman correlation,
rho 5 0.44, p , 0.0001). Both cTnT and ST-VM retained
their prognostic value among patients with UAP (Table 6).
DISCUSSION
This prospective study demonstrated that both early deter-
mination of cTnT and subsequent cVST for 24 h possess
independent prognostic information in the same cohort of
patients suspected of having UCAD. However, by combin-
ing early determination of cTnT and subsequent continuous
ST segment monitoring, we found that patients with both a
cTnT level $0.20 mg/liter and one ST segment (ST-VM)
episode or more were at particularly high risk (25.8% event
rate), while patients with either one of the methods positive
were at intermediate risk (3.1% event rate) of death or AMI
at 30 days. As the treatment of UCAD is cumbersome,
Figure 2. Occurrence of cardiac death or AMI during 30 days of
follow-up according to the level of cardiac troponin T and the
presence or absence of ST segment episodes at continuous vector-
cardiography ST segment monitoring. Top, Kaplan Meier curves
of event-free probability of patients (n 5 231) with troponin T
,0.20 mg/liter or troponin T $0.20 mg/liter at inclusion (log rank
test, p 5 0.0006). Bottom, Kaplan Meier curves of event-free
probability of patients (n 5 214) without or with one ST segment
(ST-VM) episode or more at continuous ST segment monitoring
within 24 h of inclusion (log rank test, p 5 0.0001). ST-VM 5 ST
vector magnitude.
Table 4. Multivariate Stepwise Cox Regression Analysis of
Potential Risk Variables in Order to Detect Independent
Predictors of Cardiac Death or Acute Myocardial Infarction at
30 Days
Risk ratio
(95% CI) p Value
ST-VM $1 episodes 7.43 (1.54, 35.70) 0.012
Troponin T $0.20 mg/l* 3.85 (1.09, 13.52) 0.036
Calcium antagonists† 3.31 (1.05, 10.43) 0.041
*A cTnT cut-off of 0.10 mg/liter was evaluated in a separate model (see text).
†Prestudy use of calcium antagonists. All variables retained in the final model are
shown.
CI 5 confidence interval; ST-VM 5 ST vector magnitude.
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expensive and occasionally risky, treatment should be tai-
lored according to thorough considerations regarding the
underlying pathophysiology and prognosis. However,
whether specific treatment regimens will change the natural
course of the underlying coronary artery disease, and thus
the prognosis, in such patients identified as being at high or
intermediate risk is not known at present. Recent results
however, indicate that the beneficial effect of prolonged
antithrombotic treatment in cases of UCAD is more pro-
nounced in patients with elevated cTnT levels as compared
with those without (24). It is equally important to identify
patients at very low risk in whom early transmission to a
low-cost facility or even discharge from hospital may be
considered. In the present study, 3% of the patients with a
cTnT level ,0.20 mg/liter suffered the composite end-
point. This comparatively high event rate among patients
without an elevated cTnT has been emphasized as a
limitation for the use of this method alone in the prognostic
assessment of patients with UCAD (25–27). Among pa-
tients of a similar category as the present study population,
Lindahl et al. (28) identified a group with 1% risk of death
or AMI at 5 months by combining a cTnT level ,0.06
mg/liter and a low-risk predischarge exercise test response.
However, this very low-risk subgroup only constituted 9%
of the total study population. In the same series, an event
rate of 4.1% was found (in 18% of the total study popula-
tion) by combining a cTnT level ,0.20 mg/liter and a
low-risk predischarge exercise test response. Recently, Mor-
row et al. (11) investigated the predictive value of combining
an early rapid bedside qualitative assay for cTnT and
determination of CRP among patients comparable with the
present study population. Although the number of clinical
events was low in that study (event rate 1.6%), the combi-
nation of a negative cTnT (,0.20 mg/liter) and CRP ,1.55
mg/dl identified a subgroup of patients (63% of the total
study population) with a 0.36% risk of death within 14 days.
In the present study, the combination of an early cTnT level
,0.20 mg/liter and no ST segment episodes identified,
within 24 h of inclusion, a subgroup of patients with a 1.7%
Table 5. The Relationship Between the Number of ST Segment
Episodes and the Level of Cardiac Troponin T at Inclusion
Among Patients With Unstable Angina Pectoris in Whom Both
ST Segment Monitoring and Biochemical Analyses Were
Performed (n 5 140)
Number of ST-VM
Episodes
cTnT level, mg/liter
Median IQR (Range)
0 (n 5 109) 0.00 0.00–0.02 (0.00–1.09)
1–3 (n 5 16) 0.02 0.00–0.05 (0.00–0.32)
$4 (n 5 15) 0.03 0.00–0.11 (0.00–2.00)
Spearman correlation, rho 5 0.44, p , 0.0001. IQR 5 interquartile range;
ST-VM 5 ST vector magnitude.
Table 6. Occurrence of Cardiac Death/AMI at 30 Days
According to the Level of Cardiac Troponin T at Inclusion and
Continuous ST Segment Monitoring in the Subset of Patients
With Unstable Angina Pectoris (n 5 152)
Death or
AMI
p Value
(Log-rank)
Cardiac troponin T
,0.20 mg/liter (n 5 142) 3 (2)
$0.20 mg/liter (n 5 9) 2 (22) 0.001
ST segment monitoring
ST-VM ,1 episodes (n 5 110) 1 (1)
ST-VM $1 episodes (n 5 31) 4 (13) 0.002
Values shown are numbers of patients and percentages of the group. Note: the blood
sample was lost in one patient. The total number of patients in the two groups differs
because not all patients with a troponin T measurement had continuous ST segment
monitoring analysis performed. ST-VM 5 ST vector magnitude.
Figure 3. Flow of patients according to the level of cardiac troponin T at inclusion (cut-off value 0.20 mg/liter), the presence or absence
of ST segment (ST-VM) episodes at continuous vectorcardiography ST segment monitoring within 24 h of inclusion, and event rate
(cardiac death or myocardial infarction) after 30 days of follow-up. In 18 patients, no cVST analysis was performed due to the presence
of bundle branch block, ,16 h of cVST performed or because of technical problems. cTnT 5 cardiac troponin T. ST-VM 5 ST vector
magnitude.
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risk of death or AMI. The fact that this low-risk group
comprised more than 50% of the total study population is of
considerable importance, as these patients may be consid-
ered for early transmission to a less costly facility than the
intensive care setting.
Relationship between ST segment changes and the level
of troponin T. Previous studies have demonstrated that
the risk of a poor clinical outcome in patients with UCAD
increases with the detection of increasing blood levels of
sensitive and specific markers of myocardial damage such as
the troponins (7,10,29,30). This quantitative relationship,
however, in particular among patients in whom myocardial
infarction has been ruled out by classic markers such as
CK-MB, is poorly understood. In the present study, it was
demonstrated that patients with episodes of transient myo-
cardial ischemia detected by cVST had higher levels of
cTnT than patients without. Therefore, it might be specu-
lated that elevated cTnT levels represent a summation of
prolonged myocardial ischemia leading to a poor clinical
outcome. However, in the present study, there was only a
moderate relationship between the number of transient
ischemic episodes and the level of cTnT at inclusion (rho 5
0.45). This might be explained by the fact that the signals
detected by the two methods reflect different time phases of
the ischemic process. Moreover, in the present study, the
number of ischemic episodes during cVST was influenced
by the antithrombotic therapies (18). Hence, these subjects
need further investigation in future studies.
Patients ineligible for continuous vectorcardiography ST
segment monitoring analysis. An obvious limitation of
cVST is the loss of data due to technical problems. In the
present study, five (2.2%) patients could not be adequately
monitored for this reason. In addition, 13 (5.6%) patients
were prospectively excluded from cVCT analysis due to the
presence of bundle branch block or monitoring time ,16 h,
as cVST has not yet been validated in such patients. These
shortcomings are in accordance with previous observations
(16,17). Our results indicate that patients ineligible of cVST
analysis are at higher risk for subsequent serious cardiac
events, and that early risk assessment of these patients may
be performed by the use of sensitive biochemical markers.
However, other clinical characteristics associated with a
poorer prognosis, e.g., bundle branch block, may be present
in patients ineligible of cVST analysis as compared with the
rest of the study population. Thus, the role of an elevated
cTnT level as an independent predictor of adverse clinical
outcome in patients ineligible of cVST analysis should be
investigated in future and larger trials.
The prognostic value of ECG at inclusion. After multi-
variate analysis of potential baseline risk variables, ST
segment depression was found to be the strongest predictor
of adverse outcome in the present study. The association
between ECG ST segment depression and a poor clinical
outcome in patients with UCAD is consistent with previous
findings (7,9,13,14,17,23,29,30). However, we found that
ST segment depression at inclusion did not add additional
prognostic information once the prognostic value of cTnT
and cVST, respectively, was considered. Conflicting results
have been reported in cases of UCAD with regard to the
independent prognostic information of the cTnT level as
compared with ST segment depression at the admission
ECG (9,23,29). In contrast, ST segment changes on am-
bulatory ECG monitoring seem to be more prognostically
powerful than ECG ST segment depression at admission
(13,14).
Study limitations. The present investigation was per-
formed as a substudy in a multicenter trial with several
exclusion criteria, thus, our findings may be less represen-
tative in a more general UCAD population. The prognostic
value of cardiac troponin T in particular might be favored by
the exclusion of patients with renal failure (9,20,31). The
interpretation of ECG changes in the present study was
carried out by the local investigators, therefore, a central
evaluation with strict prospectively defined ECG criteria
could have altered the prognostic value of the ECG find-
ings.
Conclusions. Employment of cTnT and cVST are valu-
able for the risk assessment of patients with UCAD. This
study demonstrates that the risk assessment of patients
suspected of having UCAD can be substantially improved
by adding 24 h of cVST for an early determination of cTnT.
Cost benefit and safety in patients triaged to aggressive
antithrombotic or early referral to a low-cost fascility (or
even discharge), according to the information derived from
the combination of biochemical markers and cVST, needs
delineation in future prospective trials.
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